- Home
- BRBR vs APGE Comparison
BRBR vs APGE Comparison
Compare BRBR & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRBR | APGE |
|---|---|---|
| Founded | 2019 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.7B |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | BRBR | APGE |
|---|---|---|
| Price | $16.97 | $72.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 11 |
| Target Price | $43.56 | ★ $102.40 |
| AVG Volume (30 Days) | ★ 2.9M | 745.9K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $2,316,600,000.00 | N/A |
| Revenue This Year | $6.36 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | $48.94 | ★ N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $16.05 | $26.20 |
| 52 Week High | $79.57 | $84.56 |
Technical Indicators
Market Signals| Indicator | BRBR | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 34.98 | 53.49 |
| Support Level | N/A | $35.24 |
| Resistance Level | $19.35 | $82.77 |
| Average True Range (ATR) | 0.97 | 3.69 |
| MACD | 0.17 | 0.64 |
| Stochastic Oscillator | 22.38 | 58.20 |
Price Performance
Historical ComparisonAbout BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.